Format

Send to

Choose Destination
Arthritis Care Res (Hoboken). 2020 Mar 7. doi: 10.1002/acr.24176. [Epub ahead of print]

A cautious hope for cannabidiol (CBD) in rheumatology care.

Author information

1
Alan Edwards Pain Management Unit, McGill University Health Centre, Quebec, Canada.
2
Division of Rheumatology, McGill University Health Centre, Quebec, Canada.
3
Departments of Anesthesiology, Medicine (Rheumatology), and Psychiatry, University of Michigan Medical School, Ann Arbor, Michigan.
4
Health Care Center for Pain Medicine, Mental Health Saarbrücken- St.Johann, Saarbrücken, Germany.
5
Department of Psychosomatic Medicine and Psychotherapy, Technische Universität München, München, Germany.

Abstract

Cannabidiol (CBD), a major metabolite of Cannabis sativa, is popularized as a medicinal product, with potential for analgesic, anti-inflammatory and antioxidant effects. CBD may hold promise as a treatment in rheumatic diseases, but evidence to date remains preclinical. Preclinical effects on pain and inflammation is encouraging, but clinical study is lacking with only a single study in knee osteoarthritis reporting promising effect on symptoms. CBD products are freely available over the counter and marketed as food supplements or wellness products. The World Health Organization has identified pure CBD as safe and without abuse potential, but products are not subject to drug regulatory standards leading to inconsistency in manufacturing practices and quality of products. Not only have molecular concentrations of CBD been identified as inaccurate, but there are concerns for contaminants including heavy metals, pesticides, microbes and mycotoxins, as well as added THC. Drug-drug interactions pose a potential risk due to metabolism via the CYP P450 enzyme pathway. Patients wishing to use CBD should obtain a product with certification of Good Manufacturing Practices, initiate treatment with a nighttime low dose and have defined outcome goals within a reasonable time frame. Treatments should not be managed by non-medical dispensary personnel. The hope that CBD may be a useful therapy must be substantiated by sound scientific study.

KEYWORDS:

cannabidiol; rheumatic disease

PMID:
32144889
DOI:
10.1002/acr.24176

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center